Profund Advisors LLC Has $11.32 Million Stake in Illumina, Inc. (ILMN)

Profund Advisors LLC reduced its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 5.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,235 shares of the life sciences company’s stock after selling 3,908 shares during the quarter. Illumina accounts for about 0.5% of Profund Advisors LLC’s holdings, making the stock its 29th biggest position. Profund Advisors LLC’s holdings in Illumina were worth $11,320,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Penserra Capital Management LLC boosted its holdings in Illumina by 13.0% during the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock worth $153,000 after purchasing an additional 102 shares during the last quarter. Paradigm Asset Management Co. LLC boosted its holdings in Illumina by 5.6% during the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after purchasing an additional 50 shares during the last quarter. Patten Group Inc. boosted its holdings in Illumina by 2.7% during the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after purchasing an additional 25 shares during the last quarter. NN Investment Partners Holdings N.V. boosted its holdings in Illumina by 11.3% during the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock worth $171,000 after purchasing an additional 100 shares during the last quarter. Finally, Bronfman E.L. Rothschild L.P. boosted its holdings in Illumina by 3.6% during the first quarter. Bronfman E.L. Rothschild L.P. now owns 1,198 shares of the life sciences company’s stock worth $204,000 after purchasing an additional 42 shares during the last quarter. Hedge funds and other institutional investors own 93.34% of the company’s stock.

Illumina, Inc. (NASDAQ ILMN) traded down 0.15% during trading on Friday, reaching $210.72. 942,620 shares of the company’s stock were exchanged. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $214.34. The stock’s 50-day moving average is $197.88 and its 200-day moving average is $180.42. The company has a market cap of $30.77 billion, a P/E ratio of 42.28 and a beta of 0.81.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The company had revenue of $662.00 million for the quarter, compared to analysts’ expectations of $642.38 million. During the same quarter in the previous year, the business posted $0.86 earnings per share. Illumina’s quarterly revenue was up 10.3% on a year-over-year basis. Analysts predict that Illumina, Inc. will post $3.65 EPS for the current fiscal year.

ILMN has been the topic of several research reports. Deutsche Bank AG set a $175.00 price objective on shares of Illumina and gave the stock a “hold” rating in a research report on Friday, July 28th. Canaccord Genuity raised shares of Illumina from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $170.00 to $215.00 in a research report on Monday, August 7th. Morgan Stanley reaffirmed an “underweight” rating and issued a $122.00 price objective (up previously from $115.00) on shares of Illumina in a research report on Monday, July 10th. Vetr lowered shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price objective on the stock. in a research report on Wednesday, June 21st. Finally, Barclays PLC reaffirmed a “hold” rating and issued a $150.00 price objective on shares of Illumina in a research report on Wednesday, July 19th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $181.76.

WARNING: This story was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://stocknewstimes.com/2017/09/16/profund-advisors-llc-has-11-32-million-stake-in-illumina-inc-ilmn.html.

In related news, CAO Michel Bouchard sold 616 shares of the business’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $200.00, for a total value of $123,200.00. Following the sale, the chief accounting officer now owns 15,161 shares in the company, valued at $3,032,200. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Charles Dadswell sold 145 shares of the business’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $174.24, for a total transaction of $25,264.80. Following the completion of the sale, the senior vice president now owns 10,646 shares in the company, valued at approximately $1,854,959.04. The disclosure for this sale can be found here. Insiders sold 195,434 shares of company stock worth $37,480,647 in the last 90 days. 1.60% of the stock is currently owned by company insiders.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply